Glen Hanson

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City 84112, USA
    J Neurochem 82:1171-8. 2002
  2. pmc Response of Neurotensin Basal Ganglia Systems during Extinction of Methamphetamine Self-Administration in Rat
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Room 112 Skaggs Hall, Salt Lake City, UT 84112
    J Pharmacol Exp Ther 346:173-81. 2013
  3. pmc Response of limbic neurotensin systems to methamphetamine self-administration
    G R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, 84112, USA
    Neuroscience 203:99-107. 2012
  4. ncbi request reprint The methamphetamine experience: a NIDA partnership
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 112, Salt Lake City, UT 84112, USA
    Neuropharmacology 47:92-100. 2004
  5. ncbi request reprint Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Ann N Y Acad Sci 1025:146-50. 2004
  6. ncbi request reprint Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors
    Veronica Sandoval
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 22:8705-10. 2002
  7. pmc Mechanisms underlying methamphetamine-induced dopamine transporter complex formation
    Gregory C Hadlock
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 329:169-74. 2009
  8. ncbi request reprint Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism
    Anthony J Baucum
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 24:3436-43. 2004
  9. ncbi request reprint Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors
    Yvette V Ugarte
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 472:165-71. 2003
  10. ncbi request reprint Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity
    J Paul Hansen
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 300:1093-100. 2002

Research Grants

Collaborators

Detail Information

Publications61

  1. ncbi request reprint Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City 84112, USA
    J Neurochem 82:1171-8. 2002
    ..This study demonstrated opposite responses of the basal ganglia SP system to low and high doses of methamphetamine and suggested that a combination of dopamine D1 and D2 receptor activity contributed to these effects...
  2. pmc Response of Neurotensin Basal Ganglia Systems during Extinction of Methamphetamine Self-Administration in Rat
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Room 112 Skaggs Hall, Salt Lake City, UT 84112
    J Pharmacol Exp Ther 346:173-81. 2013
    ..In summary, these findings support the hypothesis that some of the endogenous basal ganglia NT systems contribute to the elimination of contingent behavior during the early stages of the METH SA extinction process. ..
  3. pmc Response of limbic neurotensin systems to methamphetamine self-administration
    G R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, 84112, USA
    Neuroscience 203:99-107. 2012
    ..After 5 days in SAM animals, NT levels were also elevated in the ventral tegmental area, but not frontal cortex of rats self-administering METH...
  4. ncbi request reprint The methamphetamine experience: a NIDA partnership
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 112, Salt Lake City, UT 84112, USA
    Neuropharmacology 47:92-100. 2004
    ....
  5. ncbi request reprint Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Ann N Y Acad Sci 1025:146-50. 2004
    ....
  6. ncbi request reprint Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors
    Veronica Sandoval
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 22:8705-10. 2002
    ..These observations suggest a role for DA in the MPD-induced redistribution of VMAT-2. The implications of this phenomenon will be discussed...
  7. pmc Mechanisms underlying methamphetamine-induced dopamine transporter complex formation
    Gregory C Hadlock
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 329:169-74. 2009
    ..Furthermore, these data suggest a multifaceted role for D2 receptors in mediating METH-induced alterations of the DAT and its function...
  8. ncbi request reprint Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism
    Anthony J Baucum
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 24:3436-43. 2004
    ..The implications of this phenomenon with regard to the neurotoxic potential of these stimulants are discussed...
  9. ncbi request reprint Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors
    Yvette V Ugarte
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 472:165-71. 2003
    ..Unlike methamphetamine, the dopamine reuptake inhibitors, methylphenidate and cocaine, rapidly increased vesicular dopamine uptake. The implications of these phenomena are discussed...
  10. ncbi request reprint Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity
    J Paul Hansen
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 300:1093-100. 2002
    ..Taken together, these results reveal several differences between effects of MDMA and previously reported METH on DAT and VMAT-2; differences that may underlie the dissimilar neurotoxic profile of these agents...
  11. ncbi request reprint Ceramide-induced alterations in dopamine transporter function
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Room 201, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 458:31-6. 2003
    ..e., which presumably competes for uptake with 5-HT). Taken together, these results reveal that ceramide is a novel modulator of monoamine transporter function, and may alter the affinity of dopamine transporters for its primary substrate...
  12. ncbi request reprint Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression
    Kamisha L Johnson-Davis
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurochem 82:1472-9. 2002
    ..These data suggest that neurotoxic regimens of methamphetamine induce changes in striatonigral neurons that persist for up to 3 months, although there is some recovery...
  13. ncbi request reprint Inhibitory effect of reserpine on dopamine transporter function
    Ryan R Metzger
    Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City 84112, USA
    Eur J Pharmacol 456:39-43. 2002
    ..Taken together, these data suggest that reserpine may transiently alter dopamine transporter function in a noncompetitive, indirect manner...
  14. ncbi request reprint A single methamphetamine administration rapidly decreases vesicular dopamine uptake
    Jeffrey M Brown
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 302:497-501. 2002
    ..These studies provide further evidence that psychostimulants rapidly and differentially modify vesicular DA uptake. In addition, these studies demonstrate a complex role for D(2) DA receptors in altering vesicular DA transport...
  15. ncbi request reprint Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix
    David H Adams
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurochem 84:87-93. 2003
    ....
  16. ncbi request reprint New insights into the mechanism of action of amphetamines
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Annu Rev Pharmacol Toxicol 47:681-98. 2007
    ..All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases...
  17. pmc Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine
    Paul S Frankel
    University of Utah, Department of Pharmacology and Toxicology, Salt Lake City, UT 84112, USA
    Pharmacol Biochem Behav 86:511-5. 2007
    ..Taken together, these results suggest that the accumulation of drug in animals pretreated with high-dose METH contributes to the overall enhanced behavioral response following challenges with low-doses of METH...
  18. ncbi request reprint Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Addiction 102:44-8. 2007
    ..To review studies delineating the neurotoxic effects of methamphetamine on monoamine transport in dopaminergic neurons of the striatum and nucleus accumbens...
  19. pmc Brain levels of neuropeptides in human chronic methamphetamine users
    Paul S Frankel
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Neuropharmacology 53:447-54. 2007
    ....
  20. pmc Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system
    Mario E Alburges
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA
    Eur J Pharmacol 573:124-32. 2007
    ....
  21. pmc Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation
    Gregory C Hadlock
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 335:207-12. 2010
    ....
  22. pmc Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users
    Paul S Frankel
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA
    Neuropharmacology 55:41-6. 2008
    ..Our postmortem brain data suggest involvement of striatal dynorphin systems in human cocaine users and should add to the interest in the testing of new dynorphin-related therapeutics for the treatment of cocaine addiction...
  23. pmc Responses of limbic and extrapyramidal substance P systems to nicotine treatment
    Mario E Alburges
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT, USA
    Psychopharmacology (Berl) 201:517-27. 2009
    ..The effects of nicotine on these dopamine systems have also been extensively studied; however, its effects on the associated SP pathways have received little attention...
  24. doi request reprint Differential response of neurotensin to methamphetamine self-administration
    Paul S Frankel
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA
    Ann N Y Acad Sci 1139:112-7. 2008
    ....
  25. ncbi request reprint Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism
    Kristen A Horner
    Department of Pharmacology and Toxicology, 30 South 2000 East, Rm 201, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 319:414-21. 2006
    ..These findings suggest that exposure to multiple, high doses of METH increases the number of neurons expressing detectable levels of ppNPY mRNA and that this phenomenon is dependent on DA D1-receptor activation...
  26. ncbi request reprint Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201 84112, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 449:71-4. 2002
    ..These data suggest that psychostimulants acutely and differentially affect VMAT-2 subcellular localization...
  27. ncbi request reprint Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats
    Kamisha L Johnson-Davis
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201, Salt Lake City, UT 84112, USA
    Neurotox Res 5:273-81. 2003
    ..These data suggest that Kappa-agonists do not protect against methamphetamine-induced toxicity to monoamines in rats, and may potentiate mortality when co-administered with methamphetamine...
  28. pmc Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Eur J Pharmacol 571:25-8. 2007
    ..These data represent the first report that amphetamine redistributes VMAT-2 protein. In addition, these data demonstrate that the trafficking of VMAT-2 after amphetamine or methylphenidate is selective for monoaminergic neurons...
  29. ncbi request reprint Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration
    Jannine G Truong
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 492:143-7. 2004
    ..This effect of apomorphine on vesicular dopamine uptake was blocked by pretreating with eticlopride, a dopamine D2 receptor antagonist. The implications of these findings relevant to the treatment of neurodegeneration are discussed...
  30. ncbi request reprint Bupropion increases striatal vesicular monoamine transport
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Neuropharmacology 49:820-30. 2005
    ..The findings from this study demonstrate similarities and differences in the mechanism by which MPD and bupropion affect striatal dopaminergic nerve terminals...
  31. ncbi request reprint Differential neurotensin responses to low and high doses of methamphetamine in the terminal regions of striatal efferents
    Paul S Frankel
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, 84112, USA
    Eur J Pharmacol 522:47-54. 2005
    ....
  32. ncbi request reprint Impact of psychostimulants on vesicular monoamine transporter function
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 479:283-9. 2003
    ..As described in this review, these studies not only provide insight into the pharmacological actions of stimulants, but also mechanisms underlying neurodegenerative disorders, including Parkinson's disease...
  33. ncbi request reprint Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration
    Jannine G Truong
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 474:223-6. 2003
    ..The implications of this finding relevant to the treatment of neurodegenerative disorders are discussed...
  34. ncbi request reprint Tolerance to the neurotoxic effects of methamphetamine in young rats
    Evan L Riddle
    University of Utah, Department of Pharmacology and Toxicology, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 435:181-5. 2002
    ..The methamphetamine biweekly pretreatment attenuated the hyperthermia caused by the neurotoxic methamphetamine regimen; a phenomenon that may have contributed to the neuroprotection...
  35. pmc Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 327:161-7. 2008
    ....
  36. pmc Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Synapse 63:147-51. 2009
    ....
  37. pmc Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation
    Sarah J Farnsworth
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 328:807-12. 2009
    ..These findings provide insight into not only the mechanism of action of cocaine but also mechanisms underlying the regulation of dopaminergic neurons...
  38. ncbi request reprint Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein
    Jannine G Truong
    University of Utah, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 504:27-32. 2004
    ..Taken together, these data demonstrate that dopamine D2 receptor subtype activation increases vesicular dopamine uptake. Implications of this phenomenon with regard to the treatment of Parkinson's disease will be discussed...
  39. ncbi request reprint Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Neurosci Methods 155:109-15. 2006
    ....
  40. ncbi request reprint Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity
    Jannine G Truong
    University of Utah, Salt Lake City, 84112, USA
    J Pharmacol Exp Ther 314:1087-92. 2005
    ..Implications with regard to methamphetamine-induced dopaminergic deficits, as well as dopamine-associated neurodegenerative disorders such as Parkinson's disease, are discussed...
  41. pmc Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release
    Pei Wen Chu
    Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurochem 115:325-32. 2010
    ..These may contribute to both the decrease in K(+)-stimulated DA release and the persistent dopaminergic deficits caused by METH...
  42. pmc Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    J Neurosci Methods 177:177-82. 2009
    ..Accordingly, this in vitro model may help to advance the treatment of disorders involving abnormal DA disposition including Parkinson's disease, attention-deficit hyperactivity disorder, and substance abuse...
  43. ncbi request reprint Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, 84112, USA
    Synapse 60:474-7. 2006
    ..PND 88-92 rats. However, decreased VMAT-2 density in PND 38-42 rats reduces V(max), which in turn lowers DA uptake...
  44. ncbi request reprint Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits
    Veronica Sandoval
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 304:1181-7. 2003
    ..These findings not only provide insight into the neurotoxic effects of methamphetamine but also mechanisms underlying dopamine neurodegenerative disorders, including Parkinson's disease...
  45. pmc Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, United States
    J Neurosci Methods 180:317-20. 2009
    ..These results may also be applicable to the study of frozen human brain tissue...
  46. pmc Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment
    Jarom E Hanson
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 607:68-73. 2009
    ....
  47. ncbi request reprint Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 323:738-45. 2007
    ....
  48. ncbi request reprint Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Rm 201, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 318:676-82. 2006
    ..These findings suggest a link between METH-induced alterations in serotonergic hippocampal vesicular uptake and the persistent hippocampal serotonergic deficits induced by the stimulant...
  49. pmc Methylphenidate-induced alterations in synaptic vesicle trafficking and activity
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA
    Ann N Y Acad Sci 1139:285-90. 2008
    ..These findings may provide important insights useful for understanding and treating disorders involving abnormal DA transmission including drug abuse, Parkinson's disease, and attention-deficit hyperactivity disorder...
  50. pmc Differential regional effects of methamphetamine on dopamine transport
    Pei Wen Chu
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 590:105-10. 2008
    ....
  51. ncbi request reprint Phencyclidine increases vesicular dopamine uptake
    Michael J Crosby
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 438:75-8. 2002
    ..These data demonstrate a heretofore unreported mechanism that may contribute to the ability of PCP to influence dopamine neuronal function and exert its pharmacological effects...
  52. pmc Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Neuropharmacology 56:133-8. 2009
    ..In addition, these findings may contribute to our understanding of the pathogenesis of a variety of DA-related disorders such as substance abuse and Parkinson's disease and also suggest new therapeutic targets for treating such diseases...
  53. ncbi request reprint 3,4-Methylenedioxymethamphetamine increases neuropeptide messenger RNA expression in rat striatum
    David H Adams
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201, Salt Lake City, UT 84112 5820, USA
    Brain Res Mol Brain Res 133:131-42. 2005
    ....
  54. ncbi request reprint The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Neurochem 101:883-8. 2007
    ....
  55. pmc Mechanisms of methamphetamine-induced dopaminergic neurotoxicity
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    AAPS J 8:E413-8. 2006
    ..This review will describe the current understanding of how high-dose METH administration leads to the production of these toxic reactive species and consequent permanent dopaminergic deficits...
  56. pmc Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia
    Paul S Frankel
    Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 336:809-15. 2011
    ....
  57. pmc Role of monoamine transporters in mediating psychostimulant effects
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    AAPS J 7:E847-51. 2005
    ....
  58. ncbi request reprint Age-dependent effects of methamphetamine on VMAT-2
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 201, Salt Lake City, UT 84112, USA
    Ann N Y Acad Sci 1074:154-9. 2006
    ....
  59. ncbi request reprint Putting drug abuse research to use in real-life settings
    Glen R Hanson
    National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4123, Bethesda, MD 20892, USA
    J Subst Abuse Treat 23:69-70. 2002
  60. ncbi request reprint NeuroAIDS, drug abuse, and inflammation: building collaborative research activities
    Joan W Berman
    Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Neuroimmune Pharmacol 1:351-99. 2006
    ..Research priorities were identified. Additional information about this meeting is available through links from the NIDA AIDS Research Program website ( http://www.nida.nih.gov/about/organization/arp/arp-websites.htm )...
  61. pmc Two perspectives, one goal
    Glen R Hanson
    Sci Pract Perspect 1:2. 2002

Research Grants20

  1. Pharmacology and Toxicology of Methamphetamine Abuse (K05 DA00378)
    Glen Hanson; Fiscal Year: 2007
    This is a competitive renewal application for Dr. Glen Hanson's Senior Scientist Award. Dr. Hanson is a tenured professor in the Department of Pharmacol. & Tox...
  2. "Neurochemical Alterations By Designer Drugs"
    Glen R Hanson; Fiscal Year: 2010
    ..This will identify how the VATR components link with the various effects on monoamine systems and different expressions of monoamine toxicity associated with these distinct phenylethylamine analogs. ..
  3. NEUROCHEMICAL ALTERATIONS BY DESIGNER DRUGS
    Glen Hanson; Fiscal Year: 2007
    ..This will identify how the VATR components link with the various effects on monoamine systems and different expressions of monoamine toxicity associated with these distinct phenylethylamine analogs. ..
  4. NEUROTENSIN AND METHAMPHETAMINE EFFECTS
    Glen Hanson; Fiscal Year: 2007
    ..abstract_text> ..
  5. NEUROTENSIN AND METHAMPHETAMINE EFFECTS
    Glen Hanson; Fiscal Year: 2000
    ..These studies may lead to a better appreciation of the neurobiology of these systems and improved therapies for problems associated with METH abuse as well as extrapyramidal/limbic dysfunctions. ..